TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21256403

Group type: EXPERIMENTAL
Intervention: Dentifrice A (1450 ppm fluoride as NaF, 50000 ppm KNO3) plus 450 ppm fluoride (NaF) rinse
Number of subjects: 36

Group type: COMPARATOR
Intervention: Dentifrice A plus sterile water rinse
Number of subjects: 36

Group type: COMPARATOR
Intervention: Dentifrice B (fluoride-free Dentifrice A) plus sterile water rinse
Number of subjects: 36

Group type: COMPARATOR
Intervention: Dentifrice B plus 450 ppm fluoride (NaF) rinse
Number of subjects: 36

Group type: COMPARATOR
Intervention: Dentifrice C (1000 ppm fluorine as sodium monofluorophosphate, 450 ppm fluoride as NaF) plus sterile water rinse
Number of subjects: 36
Study: 18076252

Group type: EXPERIMENTAL
Intervention: Raisins
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sports Gel
Number of subjects: 8
Study: 16123554

Group type: EXPERIMENTAL
Intervention: Deep sclerectomy with low-dosage mitomycin C (DSMMC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with low-dosage mitomycin C (TPMMC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: TPMMC
Number of subjects: 40
Study: 11854873

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with general anesthesia (epidural group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: General anesthesia with immediate extubation (extubated group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: General anesthesia with postoperative ventilation (intubated group)
Number of subjects: 90
Study: 10400005

Group type: EXPERIMENTAL
Intervention: Nesiritide (0.015, 0.03, and 0.06 microg/kg/min) administered by continuous intravenous infusion over 24 h
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 7547820

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg temazepam elixir
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg temazepam elixir
Number of subjects: 22
Study: 8248349

Group type: EXPERIMENTAL
Intervention: RU 486 (10 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3827169

Group type: EXPERIMENTAL
Intervention: Optical internal urethrotomy without catheter
Number of subjects: 54

Group type: COMPARATOR
Intervention: Optical internal urethrotomy with catheter for one day
Number of subjects: 54
Study: 30249417

Group type: EXPERIMENTAL
Intervention: Active neurostimulation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham neurostimulation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups during open-label extension
Number of subjects: 25
Study: 26750741

Group type: EXPERIMENTAL
Intervention: CRE readmission score (derived from predictors)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: CRE readmission score (validation set)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Predictors of persistent CRE carriage
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: C statistics for the model and score
Number of subjects: 168
Study: 26482090

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 1026

Group type: COMPARATOR
Intervention: Control (no BI)
Number of subjects: 1026
Study: 23527884

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subcallosal cingulate (SCC) with longer pulse widths (270-450 μs)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subcallosal cingulate (SCC) with frequency changes
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Open-label therapy after optimization
Number of subjects: 4
Study: 21228310

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg twice daily for 6 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 19149330

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral program
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 174
Study: 16570894

Group type: EXPERIMENTAL
Intervention: 35 mg risedronate once weekly for 6 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 24
Study: 12756640

Group type: EXPERIMENTAL
Intervention: Systemic cephalexin and ethyl lactate shampoo therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Systemic cephalexin therapy
Number of subjects: 20
Study: 10683351

Group type: EXPERIMENTAL
Intervention: Irrigated-tip catheter
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional catheter
Number of subjects: 50
Study: 9510449

Group type: EXPERIMENTAL
Intervention: Dietary treatment for phenylketonuria (PKU)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy gender‐, age‐, weight‐ and height‐matched controls
Number of subjects: 14
Study: 7835362

Group type: EXPERIMENTAL
Intervention: Metoprolol CR 200 mg once a day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once a day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo once a day
Number of subjects: 18
Study: 3046298

Group type: EXPERIMENTAL
Intervention: Dietary fat reduction
Number of subjects: 57
Study: 29136336

Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg single oral dose
Number of subjects: 46
Study: 26871201

Group type: EXPERIMENTAL
Intervention: 150 mg pregabalin (PGL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 500 mg starch (placebo)
Number of subjects: 100
Study: 24062546

Group type: EXPERIMENTAL
Intervention: Antenatal magnesium sulfate (MgSO4) - initial dose 4 g, maintained at 1 g/h up to maximum of 24 h
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (full-term pregnancy)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Premature pregnancy without MgSO4
Number of subjects: 72
Study: 22964926

Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol combination (400 µg budesonide and 12 µg formoterol)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Budesonide alone (400 µg)
Number of subjects: 181
Study: 20350345

Group type: EXPERIMENTAL
Intervention: Free Fruit 08
Number of subjects: 1488

Group type: EXPERIMENTAL
Intervention: Subscription 08
Number of subjects: 1488

Group type: COMPARATOR
Intervention: No Programme 08
Number of subjects: 1488

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1488
Study: 19029279

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Minimal needling
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study: 15860348

Group type: EXPERIMENTAL
Intervention: Serum BDNF levels in depressed patients
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Plasma BDNF levels in depressed patients
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Whole blood BDNF levels in depressed patients
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Serum/Blood BDNF ratio in patients with major depression
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Plasma PF4 levels in depressed subjects
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Serum PF4 levels in depressed subjects
Number of subjects: 43
Study: 12412210

Group type: EXPERIMENTAL
Intervention: sulfasalazine
Number of subjects: 33

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study: 8810809

Group type: EXPERIMENTAL
Intervention: 13C-urea (50 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 13C-urea (100 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 13C-urea (150 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 13C-urea (all doses)
Number of subjects: 39
Study: 2680084

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg daily for four weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 1191783

Group type: EXPERIMENTAL
Intervention: Scheme I: 100 rad 3 times a day, 5 days a week, total tumor dose of 8,400 rad, with 2 weeks of rest in the middle of treatment.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Scheme II: 200 rad once a day, 5 days a week, total tumor dose of 6,400 rad, with 2 weeks of rest in the middle of treatment.
Number of subjects: 45
Study: 30935934

Group type: EXPERIMENTAL
Intervention: Articles tweeted
Number of subjects: 2361

Group type: EXPERIMENTAL
Intervention: Facebook posts
Number of subjects: 2361

Group type: EXPERIMENTAL
Intervention: Number of Mendeley readers
Number of subjects: 2361

Group type: EXPERIMENTAL
Intervention: Number of Tweeters
Number of subjects: 2361

Group type: EXPERIMENTAL
Intervention: F1000 reviews
Number of subjects: 2361

Group type: EXPERIMENTAL
Intervention: Policy documents
Number of subjects: 2361
Study: 29192535

Group type: EXPERIMENTAL
Intervention: Prism Adaptation (PA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham Adaptation (SA)
Number of subjects: 70
Study: 25223324

Group type: EXPERIMENTAL
Intervention: Pencil Beam (PB) algorithm
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: X-ray Voxel Monte Carlo (MC) algorithm
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pencil Beam (PB) algorithm with hypoxic cells considered
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: X-ray Voxel Monte Carlo (MC) algorithm with hypoxic cells considered
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Renormalized plans for oxic cells
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Renormalized plans for hypoxic cells
Number of subjects: 45
Study: 23829265

Group type: EXPERIMENTAL
Intervention: Daily swimming lessons (45 minutes) in a chlorinated pool for 4 weeks
Number of subjects: 89

Group type: COMPARATOR
Intervention: Non-swimming group
Number of subjects: 89
Study: 21351116

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha 2a with ribavirin (PEG 2a + RV)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Peginterferon alpha 2a with placebo (PEG 2a + PL)
Number of subjects: 114
Study: 19647824

Group type: EXPERIMENTAL
Intervention: Clindamycin treatment
Number of subjects: 43
Study: 17384382

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 0.9% saline (NS)
Number of subjects: 28
Study: 14695860

Group type: EXPERIMENTAL
Intervention: Clinical assessment by a geriatrician or old age psychiatrist
Number of subjects: 256

Group type: COMPARATOR
Intervention: Usual care management assessment
Number of subjects: 256
Study: 11802021

Group type: EXPERIMENTAL
Intervention: Bipolar scissors tonsillectomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 200
Study: 9495396

Group type: EXPERIMENTAL
Intervention: Ephedrine 0.1 mg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ephedrine 0.2 mg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 90
Study: 7846922

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 114

Group type: COMPARATOR
Intervention: Clindamycin/Amikacin
Number of subjects: 114
Study: 2463406

Group type: EXPERIMENTAL
Intervention: 5 mg/kg diltiazem daily for 1 year
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Diltiazem therapy continued after 1 year
Number of subjects: 13
Study: 322547

Group type: EXPERIMENTAL
Intervention: Ketamine (2 mg/ml) administered by microdrip at an average rate of 10 ml/min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Innovar (0.1 ml/ml) administered by microdrip at an average rate of 10 ml/min
Number of subjects: 40
Study: 31397904

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28837725

Group type: EXPERIMENTAL
Intervention: Drain removal threshold of less than 30 mL during a 24-hour period
Number of subjects: 53

Group type: COMPARATOR
Intervention: Drain removal threshold of less than 100 mL during a 24-hour period
Number of subjects: 53
Study: 23826985

Group type: EXPERIMENTAL
Intervention: Media Smart
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (usual lessons)
Number of subjects: 51
Study: 24126948

Group type: EXPERIMENTAL
Intervention: Multiple courses of antenatal corticosteroid therapy
Number of subjects: 1724

Group type: COMPARATOR
Intervention: Single course of antenatal corticosteroid therapy
Number of subjects: 1724
Study: 23094556

Group type: EXPERIMENTAL
Intervention: Lip bumper
Number of subjects: 0

Group type: COMPARATOR
Intervention: Headgear
Number of subjects: 0
Study: 20018421

Group type: EXPERIMENTAL
Intervention: Placental drainage
Number of subjects: 36

Group type: COMPARATOR
Intervention: Clamped cord
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 17192165

Group type: EXPERIMENTAL
Intervention: Rasburicase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allopurinol (standard therapy)
Number of subjects: 0
Study: 16380617

Group type: EXPERIMENTAL
Intervention: Atomoxetine (0.5 to 1.5 mg/kg/day)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 11926625

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS)
Number of subjects: 670

Group type: COMPARATOR
Intervention: Conventional asthma therapy (CAT)
Number of subjects: 670
Study: 9616506

Group type: EXPERIMENTAL
Intervention: Budesonide (10(-9), 10(-7), and 10(-5) M)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Terbutaline (10(-8), 10(-6), and 10(-4) M)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 9
Study: 8604540

Group type: EXPERIMENTAL
Intervention: Lipoic acid 0.075 g daily for 2 months
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lipoic acid 0.15 g daily for 1 month
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (local hypotensive therapy only)
Number of subjects: 45
Study: 2561121

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEp)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural erythropoietin
Number of subjects: 0
Study: 334476

Group type: EXPERIMENTAL
Intervention: 300 mg flurbiprofen daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: 400 mg phenylbutazone daily
Number of subjects: 12
Study: 30629123

Group type: EXPERIMENTAL
Intervention: Cortical and regional β‐amyloid (Aβ) in the anterior putamen
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Cortical and regional β‐amyloid (Aβ) in the posterior putamen
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Cortical and regional β‐amyloid (Aβ) in the precuneus
Number of subjects: 269
Study: 28192627

Group type: EXPERIMENTAL
Intervention: New pathway (NP) with perioperative home visits by enterostomal therapists
Number of subjects: 218

Group type: COMPARATOR
Intervention: Standard pathway (SP)
Number of subjects: 218
Study: 25348510

Group type: EXPERIMENTAL
Intervention: Levosimendan 0.1 μg/kg/min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23562219

Group type: EXPERIMENTAL
Intervention: GLN-AA
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard-AA
Number of subjects: 19
Study: 21942782

Group type: EXPERIMENTAL
Intervention: Longer duration of item presentation (1, 5, and 10 s) with reencoding
Number of subjects: 36

Group type: COMPARATOR
Intervention: Shorter duration of item presentation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Reencoding possibility (none, immediately after the study phase, after 1 hr)
Number of subjects: 36
Study: 19369318

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study: 16776683

Group type: EXPERIMENTAL
Intervention: Recombinant cherry allergen ImmunoCAP (rPru av 1, 3 and 4)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Cherry extract
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Recombinant allergen ImmunoCAP
Number of subjects: 186

Group type: COMPARATOR
Intervention: Skin prick test (SPT)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Pru av 3 sensitization in Spanish patients
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: LTP sensitization in German patients
Number of subjects: 186
Study: 15522252

Group type: EXPERIMENTAL
Intervention: Antipsychotic medication
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11094441

Group type: EXPERIMENTAL
Intervention: Haematopoietic stem cell transplantation (HSC)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Intense regimens
Number of subjects: 350

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 350
Study: 9314625

Group type: EXPERIMENTAL
Intervention: Weight loss and exercise program (12 weekly group sessions, 1 individual session, and 6 biweekly group sessions)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Weight loss and exercise program
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual care (1 individual session, and 6 biweekly group sessions)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 64
Study: 8394192

Group type: EXPERIMENTAL
Intervention: Combination of elcatonin (carbocalcitonin) and conjugated estrogens with medroxyprogesterone acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcitonin alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conjugated estrogens with medroxyprogesterone acetate alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 3552679

Group type: EXPERIMENTAL
Intervention: High dose digoxin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Digoxin with verapamil (120 mg daily)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Digoxin with verapamil
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Digoxin and verapamil
Number of subjects: 14
Study: 31732098

Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 wk for four doses, then nivolumab 3 mg/kg every 2 wk)
Number of subjects: 1051

Group type: COMPARATOR
Intervention: Sunitinib (50 mg once daily, 4 wk on, 2 wk off)
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab
Number of subjects: 1051
Study: 30458877

Group type: EXPERIMENTAL
Intervention: Discovery then Instruction group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Instruction then Discovery group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 27053382

Group type: EXPERIMENTAL
Intervention: extruded FePP‐fortified rice (No CA/TSC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: extruded FePP‐fortified rice with CA/TSC added before extrusion (CA/TSC extruded)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: extruded FePP‐fortified rice with CA/TSC solution added after cooking (CA/TSC solution)
Number of subjects: 20

Group type: COMPARATOR
Intervention: nonextruded rice fortified with a FeSO4 solution added after cooking (reference)
Number of subjects: 20
Study: 24765679

Group type: EXPERIMENTAL
Intervention: Ureteric stent with extraction string
Number of subjects: 68

Group type: COMPARATOR
Intervention: Ureteric stent without extraction string
Number of subjects: 68
Study: 22583089

Group type: EXPERIMENTAL
Intervention: Cooperative norm
Number of subjects: 128

Group type: COMPARATOR
Intervention: Competitive norm
Number of subjects: 128

Group type: COMPARATOR
Intervention: Neutral norm
Number of subjects: 128
Study: 20420724

Group type: EXPERIMENTAL
Intervention: Automatic tube compensation (ATC)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 118
Study: 17505923

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 947
Study: 16338253

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting TAXUS stent
Number of subjects: 1314

Group type: COMPARATOR
Intervention: Bare metal stent
Number of subjects: 1314
Study: 11888954

Group type: EXPERIMENTAL
Intervention: Dental appliance
Number of subjects: 95

Group type: COMPARATOR
Intervention: UPPP
Number of subjects: 95
Study: 10443077

Group type: EXPERIMENTAL
Intervention: Bilateral ECT and flupenthixol (12‐24 mg/d)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Combined C‐ECT and flupenthixol
Number of subjects: 114

Group type: COMPARATOR
Intervention: C‐ECT alone
Number of subjects: 114

Group type: COMPARATOR
Intervention: Flupenthixol alone
Number of subjects: 114
Study: 7589058

Group type: EXPERIMENTAL
Intervention: Propranolol with ascorbic acid (2 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol without ascorbic acid (control)
Number of subjects: 0
Study: 2148876

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cyclophosphamide/methotrexate/5-fluorouracil (CMF)
Number of subjects: 214

Group type: COMPARATOR
Intervention: No adjuvant treatment (control)
Number of subjects: 214
Study: 7352858

Group type: EXPERIMENTAL
Intervention: Prednisone (40 mg/day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 43
Study: 30520976

Group type: EXPERIMENTAL
Intervention: Highest quartile of whole-body fat
Number of subjects: 3460

Group type: EXPERIMENTAL
Intervention: Highest quartile of trunk fat mass
Number of subjects: 3460

Group type: EXPERIMENTAL
Intervention: Uppermost quartile of trunk fat mass
Number of subjects: 3460
Study: 28177745

Group type: EXPERIMENTAL
Intervention: Chocolate milk
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Yogurt drink
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 2% Milk
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Fruit punch
Number of subjects: 52

Group type: COMPARATOR
Intervention: Water
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Overweight/obese children
Number of subjects: 52
Study: 26455135

Group type: EXPERIMENTAL
Intervention: Dynamic hip screw (DHS) assisted with the lesser trochanteric reduction fixation system
Number of subjects: 66

Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS) only
Number of subjects: 66
Study: 22823594

Group type: EXPERIMENTAL
Intervention: Indomethacin 75 mg slow release taken orally twice daily for 2.5 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo taken orally twice daily for 2.5 days
Number of subjects: 19
Study: 22067548

Group type: EXPERIMENTAL
Intervention: Participants reading vignettes about injury-related disabilities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants reading vignettes about illness-related disabilities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Female with an illness-related disability vignette
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visible disability vignette
Number of subjects: 0